-
Closing
April 2021
-
Sector
Technology & Innovation -
Service
M&A -
Analyticon Biotechnologies AG sold to 77 Elektronika Kft.
The owners of Analyticon Biotechnologies AG have sold their shares to Hungary-based 77 Elektronika Kft., a market leader in high-quality in vitro diagnostic devices.
Analyticon Biotechnologies AG is a global company operating in the field of in vitro diagnostics, based in Lichtenfels, Hesse. The company specialises in the core areas of urine diagnostics and haematology. For several decades, Analyticon’s products have been contributing to the reliable and highly accurate early detection of diabetes, kidney damage, infections and blood diseases. International customers, including medical practices, hospitals, clinical laboratories and OEM distributors, appreciate the ‘Made in Germany’ quality of Analyticon’s highly profitable core product portfolio.
Following a strategic restructuring within the company, which focused on realigning Analyticon’s profitable core business, the long-standing, trusting partnership with 77 Elektronika Kft. has been successfully taken to the next level through integration into their group of companies.
ConsusPartner exclusively advised the owners of Analyticon Biotechnologies AG on the sale process.
-
Partner
Looking for the right M&A advisor?
Are you the owner of a company in a similar industry and are currently (or prospectively) looking for M&A advice tailored specifically to your needs? Then we will be glad to get to know you.
From the sale of a company to succession planning, from carve-outs to corporate finance – the decisive factor for us is always to find the ideal partner and to achieve the optimum conditions for our clients in a competitive process.
Transaction overview
The shareholders of
Analyticon Biotechnologies AG, Lichtenfels
have sold all shares to the
77 Elektronika Kft., Budapest, Ungarn verkauft.
We advised the shareholders of Analyticon
Biotechnologies AG on this transaction.
Did we catch your interest?
Nothing can replace a personal conversation, especially in our industry. That’s why we look forward to getting to know you. At your or our office, on the screen or phone.
